An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Patients With Prostate Cancer.
Phase of Trial: Phase II/III
Latest Information Update: 29 Sep 2010
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 16 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2009 Planned end date changed from 1 Sep 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.